Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 18/20 | 0.48 |
| ▸ | GSK3A | P49840 | 17/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5548893 | 0.91 | GSK3A (0.49) | GSK3BGSK3AAURKACYP2D6LMNA | |
| SCHEMBL3527708 | 0.91 | GSK3A (0.57) | GSK3BGSK3ALMNAHTTRAB9A | |
| SCHEMBL3529920 | 0.90 | GSK3A (0.61) | GSK3BGSK3ALMNAHTTRAB9A | |
| SCHEMBL5550070 | 0.89 | GSK3A (0.50) | GSK3BGSK3ALMNAHTTRAB9A | |
| SCHEMBL5549831 | 0.89 | GSK3A (0.50) | GSK3BGSK3ALMNAHTTRAB9A | |
| SCHEMBL3521643 | 0.88 | GSK3A (0.43) | GSK3BGSK3AAURKACYP2D6SMN1; SMN2 | |
| SCHEMBL5548604 | 0.85 | GSK3A (0.48) | GSK3BGSK3AAURKACYP2D6LMNA | |
| SCHEMBL5548595 | 0.84 | GSK3B (0.48) | GSK3BGSK3ALMNASMN1; SMN2 | |
| SCHEMBL3528033 | 0.84 | GSK3B (0.56) | GSK3BGSK3A | |
| SCHEMBL5548481 | 0.84 | GSK3B (0.39) | GSK3BGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709473-B2 | Substituted 2H-[1,2,4]triazolo[4,3-a]pyrazines as GSK-3 inhibitors | PFIZER INC. (US) | 2010-05-04 | — | — | US | claimed |
| US-20070249612-A1 | Substituted 2H-[1,2,4]Triazolo[4,3-A]Pyrazines as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-10-25 | — | — | US | claimed |
| EP-1678180-B1 | SUBSTITUTED 2H-[1,2,4]TRIAZOLO 4,3-A PYRAZINES AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2007-08-08 | — | — | EP | claimed |
| JP-2007508290-A | — | — | 2007-04-05 | — | — | JP | claimed |
| EP-1678180-A1 | SUBSTITUTED 2H- 1,2,4 TRIAZOLO 4,3-A PYRAZINES AS GSK-3 INHIBITORS | Pfizer Products Incorporated (US) | 2006-07-12 | — | — | EP | claimed |
| WO-2005035532-A1 | SUBSTITUTED 2H-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-04-21 | — | — | WO | claimed |
| EP-1678180-B1 | SUBSTITUTED 2H-[1,2,4]TRIAZOLO 4,3-A PYRAZINES AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249612-A1 | Substituted 2H-[1,2,4]Triazolo[4,3-A]Pyrazines as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885AURKA 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.